2,816 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 1st quarter, Holdings Channel.com reports. The firm purchased 2,816 shares of the company’s stock, valued at approximately $43,000.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after purchasing an additional 134,705 shares during the period. Financial Sense Advisors Inc. grew its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock worth $6,231,000 after purchasing an additional 157,421 shares during the period. King Wealth Management Group grew its stake in shares of Teva Pharmaceutical Industries by 1,106.9% during the first quarter. King Wealth Management Group now owns 175,000 shares of the company’s stock worth $2,690,000 after purchasing an additional 160,500 shares during the period. GAMMA Investing LLC grew its stake in shares of Teva Pharmaceutical Industries by 804.7% during the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock worth $1,037,000 after purchasing an additional 60,016 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock worth $404,775,000 after purchasing an additional 300,000 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.41 on Tuesday. The business has a fifty day simple moving average of $16.70 and a 200 day simple moving average of $16.32. The company has a market capitalization of $18.83 billion, a PE ratio of -102.58, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The firm’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 earnings per share. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on TEVA shares. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a “buy” rating and a $24.00 price objective for the company. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $24.71.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,001 shares of company stock worth $996,958 in the last three months. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.